Business Context and Reporting Period
This Form 8-K was filed by OncoGenex Pharmaceuticals, Inc. on January 20, 2016. The report discloses a material event regarding the clinical development of the company's lead drug candidate, apatorsen.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial results and does not contain financial statements.
Material Changes and Clinical Results
- Phase 2 Spruce Trial Outcome: Data from the trial evaluating apatorsen in combination with carboplatin and pemetrexed for untreated metastatic non-small cell lung cancer did not reach statistical significance for progression-free survival (PFS).
- Subgroup Analysis: A potential PFS benefit was observed in the subset of patients with high baseline serum Hsp27 status.
- Study Status: The study remains ongoing.
Outlook and Management Commentary
Management expects overall survival results from the Spruce trial to be available in the second half of 2016. The company has filed a press release as Exhibit 99.1 detailing these findings.
Investor Verification Checklist
- Verify the full text of the press release filed as Exhibit 99.1 for detailed statistical data.
- Confirm the timeline for the release of overall survival data in the second half of 2016.
- Review subsequent filings for updates on the study's continuation or potential changes in development strategy.
- Check the company's most recent 10-Q or 10-K for current cash runway and liquidity status, as this 8-K does not contain financial data.